For research use only. Not for therapeutic Use.
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion[1].
The effects of Teneliximab (Chi220, BMS-224819) are not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity[2].
| Catalog Number | I042401 |
| CAS Number | 299423-37-3 |
| Purity | ≥95% |
| Reference | [1]. Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [2]. Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174(1):542-50. |
